← All trials
NCT06700148
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2024
- Primary completion
- Jan 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Nov 21, 2024
- Last posted
- Nov 21, 2024
- Enrollment
- 840
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Government of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.